Parabilis Medicines closed a $305 million Series F round to advance its Helicon‑peptide platform and push lead candidate zolucatetide toward later‑stage development. The financing, led by major life‑science investors, funds expansion of clinical programs that target intracellular or flat protein surfaces traditionally considered undruggable by small molecules. Company leadership signaled the raise supports both clinical development and potential public listing plans; Parabilis said the cash will enable larger trials and manufacturing scale‑up for peptide‑based modalities that enter cells and engage intracellular targets with high specificity.